Online inquiry

IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1666MR)

This product GTTS-WQ1666MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets GP6 gene. The antibody can be applied in Ischemic stroke research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001083899.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51206
UniProt ID Q9HCN6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1666MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4163MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BI-754111
GTTS-WQ3785MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ1057MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-621
GTTS-WQ15528MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA UCB-7858
GTTS-WQ12706MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ5419MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ2879MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AMG-761
GTTS-WQ6870MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA DX-2930
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW